Contact No: +91-8826373757 | +91-8826859373 | 011-25052216
Email: rakesh.its@gmail.com | editor@innovativepublication.com


Article Access statistics

Viewed: 209

Emailed: 0

PDF Downloaded: 60

Current Opinion in Virus and Infectious Diseases - COVID


Novel corona virus and its druggable targets


Full Text PDF Share on Facebook Share on Twitter


Review Article

Author Details : Chiragkumar J. Gohil*, Malleshappa N. Noolvi

Volume : 1, Issue : 3, Year : 2020

Article Page : 51-53


Suggest article by email

Abstract

Novel corona virus or Covid-19 is a single stranded RNA virus. It is the part of the corona virus family. The latest pandemic covid-19 is causes by the novel corona virus. The symptoms of novel corona virus infection are varying from mild to chronic. The specific and effective treatment of the novel corona virus is not available yet.
Since SARS-CoV and MERS-CoV are also part of the corona virus family and it is similar to novel corona virus, so we can identify the drug target by studying them.
Novel Corona virus has some essential structural proteins like spikes, envelop, membrane and nucleocaspid proteins, hence we can target that proteins by drugs.
In SARS-CoV, most import protein for the host cell attachments and fusion into the host cells is spikes proteins (same as of in novel corona virus). Therefore it is potential target for the development of anti-corona drugs. Including the spikes proteins, other prominent targets of novel corona virus are haemagglutinin esterase, helicase and protease.
On the other hand, utilizing the knowledge and therapy of the alternative medicinal systems like ayurvedic and homeopathic may provide better alternative for the treatment of novel corona virus/covid-19.

Keywords: Novel corona virus, Covid-19, SARS-CoV, MERS-CoV, Spikes proteins, Anti-corona drugs targets.

Doi : 10.18231/j.ijirm.2020.027

How to cite : Gohil C J, Noolvi M N, Novel corona virus and its druggable targets. Covid-19 2020;1(3):51-53

Copyright © 2020 by author(s) and Covid-19. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (creativecommons.org)